Oncology

Breast cancer treatment may cause women to enter menopause prematurely.

Top news of the day from across the health care landscape.

A first-in-class selective retinoic acid receptor alpha agonist is being tested in phase 2 clinical trials for acute myeloid leukemia and myelodysplastic syndrome.

Novel first-in-class selective retinoic acid receptor alpha agonist inhibits tumor growth in acute myeloid leukemia.

T cell responses in different tumor models are fundamentally similar.

Brandon Shank, PharmD, MPH, BCOP, discusses how pharmacists work with patients undergoing chemotherapy through transitions of care.

Study finds greater rate of opioid prescribing among cancer survivors 10 or more years past their cancer diagnosis.

Baby boomer hepatitis C virus screening rates spiked when a prompt in their electronic health records reminded a primary care provider to recommend testing.

Understudied gene provides insight into how liver cancer cells gain the nutrition necessary to proliferate.

The novel strategy could be more effective and less toxic than current chemotherapy drugs treating alternative lengthening telomere cancers.

Carolyn Choate journeys 300 miles in a kayak to honor the pharmacologist who created the lifesaving aromatase inhibitor.

Top news of the week from Specialty Pharmacy Times.

Managing chronic pain after a cancer diagnosis remains a challenge.

The new compounds may lead to a highly effective, next-line treatment for estrogen receptor-positive breast cancer.

Study is the first to provide evidence that proton-coupled amino acid transporters can be elevated in prostate cancer.

Age and tumor type most associated with initial insurance denial of cancer treatment, study finds.

Gene editing tool reveals why some patients with cancer fail to respond to immunotherapy.

Several breakthrough cancer drugs were approved in the first half of 2017.

In some cases, chemotherapy can spur cancer cells to spread to other parts of the body.

Paclitaxel chemotherapy may turn on a stress gene that allows cancer cells to escape from the primary tumor.

The receptor helps drive estrogen-receptor positive mammary tumor progression in low estrogen environments.

Understanding why some patients fail to respond to immunotherapy could improve treatments for cancer.

Study identifies previously unknown properties of gold to release anti-cancer drugs inside of tumors.

Young black women are more likely to have aggress breast cancer subtypes than white women.

Triple drug regimen effectively cured patients with hepatitis C virus after they failed to respond to a combination of two oral direct-acting antivirals.

Bruce A. Feinberg, DO, Vice President and Chief Medical Officer of Cardinal Health Specialty Solutions, discusses the expanding role of educational patient support programs in oncology.

Elderly patients with hepatitis C are typically difficult to treat due to poor tolerability and suboptimal response to interferon-based regimens.

Anti-rheumatic drug suppresses activation of a molecular pathway responsible for the disease.